Clinical Trials
11 trialsNCT00064259 2021-02-17
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00005607 2013-12-19
Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00002897 2013-09-20
Surgery With or Without Chemotherapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus
National Cancer Institute (NCI)
Phase 3 Completed
NCT00766480 2013-08-26
Study of Tissue Samples in Predicting How Well Chemotherapy and Radiation Therapy Will Kill Cancer Cells in Patients With Squamous Cell Carcinoma of the Esophagus
National Cancer Institute (NCI)
Phase NA Unknown
NCT00041262 2013-08-12
Combination Chemotherapy in Treating Patients With Esophageal Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00002884 2013-08-07
Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00629863 2013-08-07
Endoscopic Ultrasound in Diagnosing Cancer in Patients With Localized Stomach Cancer or Esophageal Cancer
National Cancer Institute (NCI)
Phase NA Completed
NCT00004257 2013-03-26
Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00019513 2012-03-23
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00008047 2009-02-09
Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00075738 2008-07-24
Fluorouracil, Irinotecan, Leucovorin, and Cisplatin as First-Line Therapy in Treating Patients With Metastatic Esophageal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown